Infectious Diseases

The American Academy of Pediatrics will continue to hold its own childhood vaccine schedule, as it has since the 1930s.

Donna Hallas, PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, shares her thoughts on how PNPs can implement evidence-based strategies to encourage parents to vaccinate their children.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

The BLA for clesrovimab was based on results demonstrated in the phase 2b/3 CLEVER trial among healthy pre-term and full-term infants.

Six-month results from the phase 2 VLA1553-221 trial aligned with initial data and demonstrated immune response at day 180 among patients aged 1 to 11 years.

The data found complements state- and national-level CDC data, confirming widespread declines in MMR vaccination rates.

In this article, we recap a timeline of recent federal agency changes to routine COVID-19 vaccination intended for the pediatric population.

Federal health agencies have adjusted COVID vaccine guidance, potentially changing eligibility and access for pediatric patients. Experts respond in this article.

New phase 3b durability data revealed nirsevimab reduced RSV hospitalizations in infants by 82.7% through 180 days vs no intervention.

Infants and toddlers with infection history were more likely to have trouble sleeping, while preschool-aged children experienced daytime tiredness.

The approved indication now includes children down to 6 weeks of age to protect against invasive meningococcal disease via serogroups A, C, W, and Y.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

These findings come as many health care professionals still report limited confidence and inconsistent practices regarding RSV immunization discussions.

NVX-CoV2705 is indicated for individuals aged 12 to 64 years with an underlying condition that poses high risk for severe COVID-19 outcomes.

Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions.

The nearly 4000 cases in 2023 were the highest number reported in over 30 years, the Task Force stated.

"These findings support Advisory Committee on Immunization Practices’ recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants," wrote the MMWR study investigators.

Current prevention strategies include 2 injectables for infants and young children, namely palivizumab and nirsevimab.

Nirsevimab significantly reduces RSV-related hospitalizations, ICU admissions, and LRTIs in infants, but doesn’t shorten hospital stays, according to a recent study.

In this article, we recap our top stories, expert interviews, and Q+A discussions from the 2025 Pediatric Academic Societies meeting.

Lea Widdice, MD, details her recent presentation at PAS 2025 on OTC STI testing within pediatrics.

"We've updated our internal clinical pathways to recommend 5 days for kids hospitalized with uncomplicated pneumonia," Cotter noted.

Shorter antibiotic courses for AOM and CAP in children proved effective across a pediatric health system, according to data presented by Elysha Pifko, MD.

Early antibiotic use before age 2 is linked to higher childhood obesity risk, with timing playing a key role in long-term weight outcomes.

Recommendations from the ACIP are forwarded to the director of the CDC, and if adopted, become official CDC policy.

A recent study found IL-6 may help with earlier sepsis detection in pregnant women, children, and newborns, outperforming traditional diagnostic tests.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the April, 2025, issue of Contemporary Pediatrics, with a special focus on pediatric allergy awareness.

A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.

Tina Tan, MD, FIDSA, FPIDS, FAAP, comments on the FDA's recent selection of the 2025-2026 influenza vaccine compositions, without the CDC's ACIP meeting and FDA's VRBPAC meeting.